Previous 10 | Next 10 |
A low dosage strength may be the reason why CureVac's (CVAC) COVID-19 vaccine demonstrated efficacy of 47% in a trial, Reuters reported.The study's lead author, Peter Kremsner of University Hospital in Tuebingen, Germany, told the news service that the poor efficacy was "very likely...
Matthias Hangst/Getty Images News After an interim analysis of a global study indicated subpar efficacy for its experimental COVID-19 vaccine, German biotech, CureVac ([[CVAC]] -41.9%) said that the rival vaccine makers could be able to use the unused manufacturing of its contractors if its o...
Gainers: Midatech Pharma (MTP) +33%.Cellect Biotechnology (APOP) +31%.iSun (ISUN) +23%.AGM Group (AGMH) +23%.Synaptogenix (SNPX) +21%9F (JFU) +18%.Capricor Therapeutics (CAPR) +15%.Clearside Biomedical (CLSD) +14%.Rezolute (RZLT) +14%.China Xiangtai Food (PLIN) +13%.Losers: ...
CureVac NV ( NASDAQ: CVAC ) slipped about 45% in the stock market on Thursday morning as the company said the late-stage trial showed its candidate COVID-19 vaccine to be only 47% effective, raising questions on the German biotech’s agreement with the European Union to delive...
Shares of German biotech CureVac (NASDAQ: CVAC) are down by a hefty 49.9% as of 9:47 a.m. EDT Thursday morning. The biotech's shares are getting walloped today in response to disappointing late-stage trial results for its COVID-19 vaccine candidate known as CVnCoV. Specifically,...
Gainers: Midatech Pharma (MTP) +37%, Cellect Biotechnology (APOP) +30%, Synaptogenix (SNPX) +24%, Clearside Biomedical (CLSD) +16%, Tiziana Life Sciences (TLSA) +16%.Losers: CureVac (CVAC) -44%, Novan (NOVN) -19%, Prothena (PRTA) -14...
Christian Kaspar-Bartke/Getty Images News BofA downgrades CureVac following disappointing COVID vaccine data Following the release yesterday of disappointing data in a phase 2b/3 trial of its COVID-19 vaccine, BofA Securities has downgraded shares of CureVac (CVAC) from buy to neutral and cut...
honglouwawa/E+ via Getty Images Though many investors remained obsessed with Fed policy before the opening bell Thursday, earnings news provided the main theme for individual stock stories during the morning. This included results from grocery store chain Kroger (KR), homebuilder Lennar (LEN)...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Shares of CureVac (NASDAQ: CVAC ) are down by nearly 50% in pre-market trading on Thursday after the Germany-based biotech firm said its first-generation Covid-19 vaccine candidate didn’t meet the pre...
CureVac (CVAC) -47% as Bill Gates-backed biotech shows below-par efficacy for COVID-19 vaccine candidate.Gaucho Group (VINO) -20%.Creatd (CRTD) -17% after proposing stock offeringNovan (NOVN) -14% after proposing capital raise.Torchlight Energy Resources (TRCH)...
News, Short Squeeze, Breakout and More Instantly...
New trial date for U.S. patent litigation set for March 3, 2025, following settlement with Acuitas Therapeutics First instance decision on validity of EP 3 708 668 B1 (split poly-A tail technology) scheduled for March 25, 2025, by European Patent Office in the context of the German patent ...
GSK acquires full rights to develop, manufacture and commercialize globally mRNA candidate vaccines for influenza and COVID-19, including combinations CureVac receives €400 million upfront and up to an additional €1.05 billion in development, regulatory and sales milestone pa...
Strategic restructuring includes a workforce reduction of approximately 30%, re-focusing on research, development, and innovation to create leaner and more agile organization Prioritization of high-value opportunities in oncology and other selected diseases, leveraging proprietary mRNA tec...